In vivo-in vitro correlation of antitumor activity of heat shock protein 90 (HSP90) inhibitors with a pharmacokinetics/pharmacodynamics analysis using NCI-N87 xenograft mice

References

• Anger GJ, Piquette-Miller M. 2008. Translational pharmacology: harnessing increased specialization of research within the basic biological sciences. Clin Pharmacol Ther. 83(6):797–801.
   PubMed Web of Science ®Google Scholar
• Banerji U. 2009. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res. 15(1):9–14.
   PubMed Web of Science ®Google Scholar
• Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. 1987. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47(4):936–942.
   PubMed Web of Science ®Google Scholar
• Chien JY, Friedrich S, Heathman MA, de Alwis DP, Sinha V. 2005. Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation. Aaps J. 7(3):E544–559.
   PubMed Web of Science ®Google Scholar
• Choo EF, Alicke B, Boggs J, Dinkel V, Gould S, Grina J, West K, Menghrajani K, Ran Y, Rudolph J, et al. 2011. Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process. Xenobiotica. 41(12):1076–1087.
   PubMed Web of Science ®Google Scholar
• Cole SPC. 1986. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol. 17(3):259–263.
   PubMed Web of Science ®Google Scholar
• Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R, Powell R, Rhodes G, Stanski D, Venitz J, et al. 2000. Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol. 40(12 Pt 2):1399–1418.
   PubMed Web of Science ®Google Scholar
• Hay MP, Hicks KO, Pruijn FB, Pchalek K, Siim BG, Wilson WR, Denny WA. 2007. Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport. J Med Chem. 50(25):6392–6404.
   PubMed Web of Science ®Google Scholar
• Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. 2013. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev. 39(4):375–387.
   PubMed Web of Science ®Google Scholar
• Hoshino-Yoshino A, Kato M, Nakano K, Ishigai M, Kudo T, Ito K. 2011. Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics/pharmacodynamics and toxicokinetics/toxicodynamics. Drug Metab Pharmacokinet. 26(6):612–620.
   PubMed Web of Science ®Google Scholar
• Isaacs JS, Xu W, Neckers L. 2003. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 3(3):213–217.
   PubMed Web of Science ®Google Scholar
• Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, et al. 2001. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 84(10):1424–1431.
   PubMed Web of Science ®Google Scholar
• Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM. 2007. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther. 323(1):346–355.
   PubMed Web of Science ®Google Scholar
• Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 425(6956):407–410.
   PubMed Web of Science ®Google Scholar
• Mader SL, Lopez A, Lawatscheck J, Luo Q, Rutz DA, Gamiz-Hernandez AP, Sattler M, Buchner J, Kaila VRI. 2020. Conformational dynamics modulate the catalytic activity of the molecular chaperone Hsp90. Nat Commun. 11(1):1410.
   PubMed Web of Science ®Google Scholar
• Mager DE, Jusko WJ. 2008. Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 83(6):909–912.
   PubMed Web of Science ®Google Scholar
• Matsuda H, Li Y, Yamahara J, Yoshikawa M. 1999. Inhibition of gastric emptying by triterpene saponin, momordin Ic, in mice: roles of blood glucose, capsaicin-sensitive sensory nerves, and central nervous system. J Pharmacol Exp Ther. 289(2):729–734.
   PubMed Web of Science ®Google Scholar
• Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, et al. 2012. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Cancer Sci. 103(2):342–349.
   PubMed Web of Science ®Google Scholar
• Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, et al. 2013. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer. Cancer Sci. 104(10):1346–1352.
   PubMed Web of Science ®Google Scholar
• Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM. 2007. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 67(7):2932–2937.
   PubMed Web of Science ®Google Scholar
• Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, et al. 2011. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res. 17(21):6831–6839.
   PubMed Web of Science ®Google Scholar
• Saitoh R, Nagayasu M, Shibahara N, Ono N, Suda A, Kato M, Ishigai M. 2014. Assessing the impact of HER2 status on the antitumor activity of an HSP90 inhibitor in human tumor xenograft mice using pharmacokinetic-pharmacodynamic modeling. Drug Metab Pharmacokinet. 29(2):185–191.
   PubMed Web of Science ®Google Scholar
• Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW, Sampath D, Wallin JJ. 2010. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos. 38(9):1436–1442.
   PubMed Web of Science ®Google Scholar
• Smith DA, Di L, Kerns EH. 2010. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 9(12):929–939.
   PubMed Web of Science ®Google Scholar
• Suda A, Kawasaki K-i, Komiyama S, Isshiki Y, Yoon D-O, Kim S-J, Na Y-J, Hasegawa K, Fukami TA, Sato S, et al. 2014. Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors. Bioorg Med Chem. 22(2):892–905.
   PubMed Web of Science ®Google Scholar
• Suda A, Koyano H, Hayase T, Hada K, Kawasaki K-I, Komiyama S, Hasegawa K, Fukami TA, Sato S, Miura T, et al. 2012. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors. Bioorg Med Chem Lett. 22(2):1136–1141.
   PubMed Web of Science ®Google Scholar
• Tsukuda T, Kawasaki K, Komiyama S, et al. 2007. HSP90 inhibitor. WO/2007/138994.
   Google Scholar
• Visser SAG, Wolters FLC, Gubbens-Stibbe JM, Tukker E, Van Der Graaf PH, Peletier LA, Danhof M. 2003. Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. J Pharmacol Exp Ther. 304(1):88–101.
   PubMed Web of Science ®Google Scholar
• Vuignier K, Schappler J, Veuthey J-L, Carrupt P-A, Martel S. 2010. Drug-protein binding: a critical review of analytical tools. Anal Bioanal Chem. 398(1):53–66.
   PubMed Web of Science ®Google Scholar
• Wong H, Alicke B, West KA, Pacheco P, La H, Januario T, Yauch RL, de Sauvage FJ, Gould SE. 2011. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res. 17(14):4682–4692.
   PubMed Web of Science ®Google Scholar
• Wong H, Belvin M, Herter S, Hoeflich KP, Murray LJ, Wong L, Choo EF. 2009. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy . J Pharmacol Exp Ther. 329(1):360–367.
   PubMed Web of Science ®Google Scholar
• Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini J-F, Yu P, Li C, Del Rosario G, Choo EF, et al. 2012. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res. 18(11):3090–3099.
   PubMed Web of Science ®Google Scholar
• Yamazaki S. 2013. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib. Aaps J. 15(2):354–366.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Nguyen L, Vekich S, Shen Z, Yin M-J, Mehta PP, Kung P-P, Vicini P. 2011. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model. J Pharmacol Exp Ther. 338(3):964–973.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, Koudriakova T. 2008. Pharmacokinetic-pharmacodynamic modeling of Biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos. 36(7):1267–1274.
   PubMed Web of Science ®Google Scholar